Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Escitalopram (escitalopram oxalate; Cipralex(®), Lexapro(®)) is a selective serotonin reuptake inhibitor (SSRI) used for the treatment of major depressive disorder (MDD) and anxiety disorder. This drug exerts a highly selective, potent, and dose-dependent inhibitory effect on the human serotonin transport. By inhibiting the reuptake of serotonin into presynaptic nerve endings, this drug enhances the activity of serotonin in the central nervous system. Escitalopram also has allosteric activity. Moreover, the possibility of interacting with other drugs is considered low. This review covers randomized, controlled studies that enrolled adult patients with MDD to evaluate the efficacy of escitalopram based on the Montgomery-Asberg Depression Rating Scale and the Hamilton Depression Rating Scale. The results showed that escitalopram was superior to placebo, and nearly equal or superior to other SSRIs (eg, citalopram, paroxetine, fluoxetine, sertraline) and serotonin-noradrenaline reuptake inhibitors (eg, duloxetine, sustained-release venlafaxine). In addition, with long-term administration, escitalopram has shown a preventive effect on MDD relapse and recurrence. Escitalopram also showed favorable tolerability, and associated adverse events were generally mild and temporary. Discontinuation symptoms were milder with escitalopram than with paroxetine. In view of the patient acceptability of escitalopram, based on both a meta-analysis and a pooled analysis, this drug was more favorable than other new antidepressants. The findings indicate that escitalopram achieved high continuity in antidepressant drug therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · cited 1×
“Escitalopram has also shown equivalent or superior efficacy to that of sustained-release venlafaxine (venlafaxine SR).(33,34)”
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Baldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100 · cited 2×
“On the other hand, another study 25 that compared variable doses of escitalopram (10–20 mg/day) and paroxetine (20–40 mg/day) revealed equivalent efficacy in the two groups.”
Klein, N., Sacher, J., Geiss-Granadia, T., Mossaheb, N., Attarbaschi, T., Lanzenberger, R., Spindelegger, C., Holik, A., Asenbaum, S., Dudczak, R., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0666-y · Cited by 62 · cited 1×
“Pharmacokinetic profile The half-life of receptor occupancy for escitalopram was calculated to be approximately 130 hours, much longer than the half-life of the plasma concentration, which was approximately 30 hours.(13) Figure 2 shows the binding occupancy of escitalopram on cerebral SERTs relative to its concentrati…”
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Cited by
Zhang, Y., Wang, Y., Wang, L., Bai, M., Zhang, X., & Zhu, X. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv025 · Cited by 104
Does escitalopram reduce neurotoxicity in major depression?
Halaris, A., Myint, A.-M., Savant, V., Meresh, E., Lim, E., Guillemin, G., Hoppensteadt, D., Fareed, J., & Sinacore, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.026 · Cited by 86
Efficacy and safety of escitalopram in treatment of severe depression in Chinese population
Si, T., Wang, G., Yang, F., Fang, Y., Fang, M., Li, J., Dong, J., Shen, X., Zhuo, J., Rui, Q., et al. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-9992-5 · Cited by 20
“%) of participants Somnolence 20 (9.0) Nausea 17 (7.7) Hyperhidrosis 10 (4.5) Dry mouth 9 (4.1) Dizziness 9 (4.1) Palpitation 5 (2.3) SS, safety analysis set; TEAE, treatmentemergent adverse events; N, total sample size; n, total number of participants in a subset”
BackgroundResultInfluentialArakawa, R., Tateno, A., Kim, W., Sakayori, T., Ogawa, K., & Okubo, Y. (2016) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2016.03.006 · Cited by 16
Jiang, K., Li, L., Xueyi, W., Fang, M., Shi, J., Cao, Q., He, J., Wang, J., Tan, W., & Hu, C. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s120190 · Cited by 18
“Overall, the tolerability findings were consistent with the previous studies 34,49–52 and did not suggest any additional safety signs for the escitalopram treatment.”
Metadata
- Authors
- Kirino, E.
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2012-12
- Volume
- 6
- Pages
- 853
- ISSN
- 1177-889X (ISSN-L)
- OpenAlex
- W2053701135
- Cited by
- 92
- References
- 7
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.